Pharmaceuticals, Biotechnology and Life Sciences
Jury selection in the New York trial of former drug company executive Martin Shkreli will enter its third day Wednesday, after some potential jurors said they could not be fair to a man who gained notoriety by raising the price of a life-saving drug more than 5,000 percent.
Former drug executive Martin Shkreli plans to hire new legal counsel to represent him against U.S. charges that he defrauded investors at his former hedge fund and a pharmaceutical company he headed, Shkreli’s current lawyers said.
Martin Shkreli, the pharmaceutical entrepreneur facing U.S. charges of securities fraud, has said he had been the target of legal authorities for his much-criticized drug-price hikes and his over-the-top public persona
Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, reported net revenue $5.6 million for the third quarter 2015.